MetaCap

Atea Pharmaceuticals (AVIR) vs Greenwich LifeSciences (GLSI)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Greenwich LifeSciences (GLSI) has outperformed Atea Pharmaceuticals (AVIR) over the past year, gaining 136.2% versus a gain of 33.3%. Over five years, GLSI leads with a -41.8% price change compared with -51.4% for AVIR. Atea Pharmaceuticals is the larger company by market cap ($318.0 million vs $282.6 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AVIR+33.33%GLSI+136.20%
+328%+154%-19%
Nov 21, 20251 yearNov 20, 2026
AVIR-51.17%GLSI-44.75%
+17%-33%-83%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AVIR versus GLSI key metrics
MetricAVIRGLSI
Share price$3.96$19.25
Market cap$318.00M$282.56M
1-day change+0.76%-2.73%
YTD return+10.92%-8.38%
1-year return+33.33%+136.20%
5-year return-51.35%-41.84%
EPS (TTM)$-1.95$-1.63
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-158.35M$-19.36M
52-week high$6.45$34.10
52-week low$2.96$7.78
Distance from 52-week high-38.60%-43.55%
Analyst consensusbuystrong_buy
Avg. price target upside+127.27%+198.70%
Average volume290.60K160.76K
Shares outstanding80.30M14.68M
Employees55—
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • GLSI has outperformed AVIR by 102.9 percentage points over the past year.

About Atea Pharmaceuticals

AVIR stock →

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV).

Health Care · Biotechnology: Pharmaceutical Preparations · 55 employees

About Greenwich LifeSciences

GLSI stock →

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients.

Health Care · Biotechnology: Pharmaceutical Preparations

AVIR vs GLSI FAQ

Which is bigger, Atea Pharmaceuticals or Greenwich LifeSciences?

Atea Pharmaceuticals (AVIR) is larger, with a market capitalization of $318.00M compared with $282.56M for Greenwich LifeSciences (GLSI).

Which stock has performed better over the past year, AVIR or GLSI?

GLSI returned +136.20% over the past 12 months, compared with +33.33% for AVIR (price return, excluding dividends). Past performance does not predict future results.

Are Atea Pharmaceuticals and Greenwich LifeSciences in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons